The sharp divergence, sovereign and passive inflows versus complete exits by top quant funds, suggests JNJ is becoming a 'barbell' stock: seen as stable cash flow (attractive to passive/sovereign) but lacking alpha (rejected by quants). Traders should monitor for further de-risking by active managers and potential dividend reinvestment demand.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $248.40entry
- T+1 · 9mo ago −0.70%α +0.22% · $246.67
- T+5 · 8mo ago −2.44%α −1.23% · $242.34
- T+20 · 8mo ago −2.44%α +5.50% · $242.34
- T+60 · 6mo ago −7.33%α −16.66% · $230.18
How similar events traded
Executive Summary
In Q4 2025, Johnson & Johnson saw a mixed institutional cluster: two major institutions, Fidelity and Norges Bank, added $8.31B in new positions, while three others, including quant powerhouses RenTech and Two Sigma, exited or trimmed holdings by $224.5M. The divergence suggests a split in institutional sentiment around JNJ’s future prospects post-divestiture of Kenvue.
Key Financial Metrics
Institutional Positions
Net institutional flow: $8.1B
▲ Buyers (2)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Fidelity | ADD | +39.7% | $3.9B | $1.4B |
| Norges Bank | NEW | +0% | $6.9B | $6.9B |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Olstein | TRIM | -40.2% | $9.0K | -$3.0K |
| RenTech | EXIT | -100% | $56.9M | -$56.9M |
| Two Sigma | NEAR_EXIT | -90.5% | $187.4M | -$167.6M |
Key Facts
- Fidelity increased its stake by 39.7%, adding 5.33M shares with a value increase of $1.39B to $3.89B.
- Norges Bank initiated a new position of 33.46M shares worth $6.92B, one of the largest new entries in the quarter.
- RenTech fully exited its $56.9M position, signaling loss of confidence from a high-conviction quant fund.
- Two Sigma reduced its stake by 90.5%, selling $167.6M in value, retaining only a minimal holding.
- Olstein Capital trimmed its small position by 40.2%, reducing exposure from $9K to $6K.
Financial Impact
Net institutional accumulation of $8.09B ($8.31B bought, $224.5M sold), driven primarily by Norges Bank's $6.92B new position and Fidelity's $1.39B add.
Risk Factors
- Growing institutional polarization may increase volatility if active managers continue exiting.
- Overreliance on passive and sovereign buyers could make the stock less responsive to fundamental catalysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-JNJ-2025-Q4 |
Track record
21 reports on JNJ
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers